An adjuvant formulation that selectively elicits the formation of antibodies of protective isotypes and of cell-mediated immunity.
about
Deviant expression of Rab5 on phagosomes containing the intracellular pathogens Mycobacterium tuberculosis and Legionella pneumophila is associated with altered phagosomal fateRecombinant bacillus calmette-guerin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal modelGenerating neutralizing antibodies, Th1 response and MHC non restricted immunogenicity of HIV-I env and gag peptides in liposomes and ISCOMs with in-built adjuvanticityAdjuvants and antibody production: dispelling the myths associated with Freund's complete and other adjuvantsNovel insights into the genetics, biochemistry, and immunocytochemistry of the 30-kilodalton major extracellular protein of Mycobacterium tuberculosisLymphocyte-selective antiproliferative and immunosuppressive effects of mycophenolic acid in mice.Mycobacterium tuberculosis and Legionella pneumophila phagosomes exhibit arrested maturation despite acquisition of Rab7.Advances in cancer vaccine development.Liposomes containing lipid A serve as an adjuvant for induction of antibody and cytotoxic T-cell responses against RTS,S malaria antigenEnhancing the protective efficacy of Mycobacterium bovis BCG vaccination against tuberculosis by boosting with the Mycobacterium tuberculosis major secretory protein.Vaccine protection against simian immunodeficiency virus infection.Pathogenicity and immune response measured in mice following intranasal challenge with enterotoxigenic Escherichia coli strains H10407 and B7A.Meningococcal lipopolysaccharide (LPS)-derived oligosaccharide-protein conjugates evoke outer membrane protein- but not LPS-specific bactericidal antibodies in mice: influence of adjuvants.Protective immunity against tuberculosis induced by vaccination with major extracellular proteins of Mycobacterium tuberculosis.Current approaches to vaccine preparation.Role of anti-idiotype vaccines in the modern treatment of human follicular lymphoma.Nonionic block polymer surfactants modulate the humoral immune response against Streptococcus pneumoniae-derived hexasaccharide-protein conjugates.Towards an off-the-shelf vaccine therapy targeting shared B-cell tumor idiotypes.Immunomodulatory agents in the laboratory and clinic.Specific features of early stage of the wound healing process occurring against the background of photodynamic therapy using fotoditazin photosensitizer-amphiphilic polymer complexes.Influence of adjuvants on protection induced by a recombinant fusion protein against malarial infection.Recombinant V antigen protects mice against pneumonic and bubonic plague caused by F1-capsule-positive and -negative strains of Yersinia pestis.Pluronic P85 enhances the efficacy of outer membrane vesicles as a subunit vaccine against Brucella melitensis challenge in miceImmunization against Porphyromonas gingivalis inhibits progression of experimental periodontitis in nonhuman primates.Glutamine synthetase of Mycobacterium tuberculosis: extracellular release and characterization of its enzymatic activityVaccine-induced protection of chimpanzees against infection by a heterologous human immunodeficiency virus type 1.Mucosal adjuvants and delivery systems for protein-, DNA- and RNA-based vaccines.Immunization with recombinant Sao protein confers protection against Streptococcus suis infection.The Mycobacterium tuberculosis phagosome interacts with early endosomes and is accessible to exogenously administered transferrin.Influence of peptide acylation, liposome incorporation, and synthetic immunomodulators on the immunogenicity of a 1-23 peptide of glycoprotein D of herpes simplex virus: implications for subunit vaccines.Inactivated simian immunodeficiency virus vaccine failed to protect rhesus macaques from intravenous or genital mucosal infection but delayed disease in intravenously exposed animalsMurine monoclonal anti-idiotope antibody breaks unresponsiveness and induces a specific antibody response to human melanoma-associated proteoglycan antigen in cynomolgus monkeys.The effect of the nonionic block copolymer pluronic P85 on gene expression in mouse muscle and antigen-presenting cells.Activation of nucleotide oligomerization domain 2 exacerbates a murine model of proteoglycan-induced arthritis.Immunization of chimpanzees confers protection against challenge with human immunodeficiency virusObservations after human immunodeficiency virus immunization and challenge of human immunodeficiency virus seropositive and seronegative chimpanzees.Novel adjuvants and delivery systems for enhancing immune responses induced by immunogens.Adjuvants.Current adjuvants and new perspectives in vaccine formulation.Development of a new therapeutic approach to B cell malignancy. The induction of immunity by the host against cell surface receptor on the tumor.
P2860
Q24548766-CF02AE9D-DE8C-46A6-87C6-52CECAAB4CF3Q24675231-A3C80D96-D370-4B0B-8D1F-C4861CF4E8BBQ24806405-C5283FFE-D0CF-430E-9A7F-62762FE0D85EQ28256294-56B88D77-F965-4895-8511-9C38B2005D31Q28486677-44E8EFE8-DA2D-43C1-A21E-33DA73C3D8D4Q33388349-F523D4A7-FD05-437E-8782-FA1DCD46DD3AQ33599349-07116F25-FFD8-4E31-A757-46152426D3F9Q33603404-68ECD9F1-6E53-4B78-B6B0-C70886D6EE20Q33755289-BDA5F447-3C1D-4885-886F-FBFD13719F2EQ33946552-40B4B890-C332-4BE6-8F35-F483239998D3Q34298187-C7C8F512-8118-42C2-BB79-C35674574F99Q34521431-B0643143-51C8-462B-9ECC-82804D32C249Q34521522-531EBBDF-7744-4260-9D4D-243D45DB728AQ34629227-92442AA7-1334-40C0-97C4-78B11DC8EA80Q34688016-FDE30E34-70F0-4220-A7CD-F044D1DE55CCQ34734310-0FDB0FF1-288D-41F5-9D55-339956607580Q35101711-892625B1-0B7D-4A59-AA40-6CDC7A7A6AD4Q35144751-D2A26B0D-F3A7-4282-9067-1C1974837E9CQ35224457-EE931C30-CCAD-49B4-A704-089CAA5AFA81Q35237689-4693BADA-2F5C-4910-B38E-9EF3A5B48469Q35504908-ADF9CC12-B8B7-44E0-BC99-15B6FC6A0BC8Q35528592-37A51B74-563C-484A-9321-8E4214A50755Q35592058-DB1EFB89-A1A0-4FD4-A2D5-6F46AC9161FAQ35775319-A4DBE0F0-BE64-44F2-AD4C-F44D1C658B34Q35781742-8FA39601-A0E9-4C16-A22A-E60D6F9BB3B9Q35848078-D96BBB86-1947-4923-8FFB-C2045871CB14Q35953762-4ECFD27C-FF33-4AB4-9B1F-F2A6108F05C3Q36097153-F921D35D-4EED-4496-A653-7A994076066AQ36367495-221E5ACB-D172-42B8-8A57-BB8B1CCBEBA8Q36800778-269680F3-AC40-46E8-BA80-2ED4B0BD7143Q36806022-4BA13886-32F2-4E19-BCF5-1560011A33FEQ36915876-5B5A66A2-FB6B-4BA2-9CCA-499622745F5BQ37155956-A8377454-2AE0-470E-BAFC-41EB040F8A96Q37283829-7AF89C9D-FBAA-4755-80FC-418E82DF6620Q37375345-8D9C2CDC-E3E0-46D9-8B99-2E8AD07DE59DQ37484317-FA8BE7C3-85FA-4048-8AF4-9D7DE9ECD4E9Q37812128-4E98CDDB-3502-4D08-AEA7-69DD76216825Q37844069-66B510B2-06A3-4008-817E-CED3067D2F31Q37909424-DF9B40CC-103D-48BF-877A-88B95C484F31Q38246919-20B4A64F-2E1B-47D1-A6B2-9EEB6288A663
P2860
An adjuvant formulation that selectively elicits the formation of antibodies of protective isotypes and of cell-mediated immunity.
description
1986 nî lūn-bûn
@nan
1986年の論文
@ja
1986年学术文章
@wuu
1986年学术文章
@zh-cn
1986年学术文章
@zh-hans
1986年学术文章
@zh-my
1986年学术文章
@zh-sg
1986年學術文章
@yue
1986年學術文章
@zh
1986年學術文章
@zh-hant
name
An adjuvant formulation that s ...... and of cell-mediated immunity.
@en
An adjuvant formulation that s ...... and of cell-mediated immunity.
@nl
type
label
An adjuvant formulation that s ...... and of cell-mediated immunity.
@en
An adjuvant formulation that s ...... and of cell-mediated immunity.
@nl
prefLabel
An adjuvant formulation that s ...... and of cell-mediated immunity.
@en
An adjuvant formulation that s ...... and of cell-mediated immunity.
@nl
P1476
An adjuvant formulation that s ...... and of cell-mediated immunity.
@en
P2093
P304
P356
10.1016/0022-1759(86)90402-3
P577
1986-12-01T00:00:00Z